Reports and Releases
FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares
FIT Biotech Oy
Company release February 14, 2018 at 5:30 PM EET
Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Suomen Itsenäisyyden Juhlarahasto Sitra ("Sitra") the Company's Board of Directors have resolved on February 14, 2018 to approve Sitra's request relating to the funding programme to convert EUR 73,000 worth of Convertible Capital Notes into the Company's K shares.
Due to the conversion of the Convertible Capital Notes, the Company transfers 19,972,640 new K shares in the Company to Sitra with the conversion price of EUR 0.003655 per share and the share capital of the Company will be increased by EUR 73,000.00. The Board authorization is based on the Extraordinary General Meeting of December 14, 2017.
The K shares will be admitted to trading on First North Finland on or about February 19, 2018.
After this transaction FIT Biotech Oy has listed shares amounting to 260,777,207 K shares.
FIT BIOTECH OY
Board of Directors
For further information:
CEO Erkki Pekkarinen
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
NASDAQ OMX Helsinki